Michel Sadelain

This inventor holds 35 USPTO granted patents and 46 published patent applications, plus 6 CIPO patents and 15 EPO patents, primarily in Immunotherapy Innovations. Top assignees: Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2002-2026.

USPTO Granted Patents = 35 (Patent Applications = 46)

% Patents Active = 94.3

CIPO Patents = 6 (Patent Applications = 31)

EPO Patents = 15 (Patent Applications = 51)

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 801(Granted Patents)

Company Filing History:

31 out of 618

Memorial Sloan Kettering Cancer Center

patents

6 out of 518

Sloan-Kettering Institute for Cancer Research

patents

5 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 2 out of 25

Memorial Hospital for Cancer and Allied Diseases

patents

5. 2 out of 854

Millennium Pharmaceuticals Limited

patents

6. 1 out of 2,166

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Immunotherapy

Chimeric Antigen Receptors

Cancer Antigen Targets

Immune Cell Compositions

T Cell Receptors

Hemoglobin Gene Therapy

Costimulatory Ligands

Tumor-Targeted T Cells

Allogeneic T-Cell Precursors

Nucleic Acids

Dihydrofolate Reductase

Anti-Ganglioside Antibodies

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697387 - CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF (2026-08-04),

2. 12345712 - Cancer antigen targets and uses thereof (2025-07-01),

3. 12331129 - Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof (2025-06-17),

4. 12275802 - Compositions and methods for immunotherapy (2025-04-14),

5. 12263220 - Compositions and methods for immunotherapy (2025-04-01),

6. 12259390 - Cancer antigen targets and uses thereof (2025-03-25),

7. 12139524 - Immune cell compositions and methods of use (2024-11-12),

8. 12036244 - Cells comprising non-HLA restricted T cell receptors (2024-07-16),

9. 12018077 - Methods of treatments using antigen-binding proteins targeting CD56 (2024-06-25),

10. 11932690 - Enhanced chimeric antigen receptors and uses thereof (2024-03-19),

11. 11753654 - Globin gene therapy for treating hemoglobinopathies (2023-09-12),

12. 11717579 - Globin gene therapy for treating hemoglobinopathies (2023-08-08),

13. 11712469 - Compositions and methods for immunotherapy (2023-08-01),

14. 11702472 - Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors (2023-07-18),

15. 11267901 - Compositions and methods for immunotherapy (2022-03-08),

Title: The Innovative Journey of Inventor Michel Sadelain

Introduction: Michel Sadelain is a renowned inventor based in New York, NY (US) known for his groundbreaking contributions to the field of biotechnology and genetic engineering.

Latest Patents: Michel Sadelain holds several patents in the areas of gene therapy, immunotherapy, and cancer treatment, showcasing his commitment to advancing medical science through innovation.

Career Highlights: With a distinguished career spanning over two decades, Michel Sadelain has made significant strides in developing novel therapies for various diseases, particularly focusing on harnessing the power of the immune system to combat cancer.

Collaborations: Throughout his career, Michel Sadelain has collaborated with leading research institutions, pharmaceutical companies, and academic partners to further his research and bring his inventions to the forefront of medical advancements.

Conclusion: Michel Sadelain's relentless pursuit of innovation and his dedication to improving patient outcomes have solidified his position as a pioneering inventor in the field of biotechnology, leaving a lasting impact on the future of healthcare.